Clinical trial
A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT02496767 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Cytokinetics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 3, 2015
- Completion date
- September 27, 2017
- Enrollment
- 744 (actual)
- Sites
- 81
Conditions
As the registry lists them; a condition with its own page is linked.